S&P 500   3,834.85 (-0.47%)
DOW   30,934.64 (-0.77%)
QQQ   325.24 (-0.34%)
AAPL   135.28 (-1.16%)
MSFT   227.32 (+1.04%)
FB   273.05 (+0.07%)
GOOGL   1,879.03 (-0.27%)
AMZN   3,285.75 (-0.64%)
TSLA   839.70 (-0.63%)
NVDA   547.12 (-1.37%)
BABA   257.09 (-1.12%)
CGC   33.32 (-0.72%)
GE   11.08 (+0.09%)
MU   84.58 (-0.51%)
AMD   95.40 (+4.23%)
NIO   58.68 (+0.58%)
T   28.65 (-0.62%)
F   11.59 (+0.52%)
ACB   10.29 (-7.88%)
BA   206.00 (-0.68%)
DIS   174.12 (+1.66%)
NFLX   581.69 (+0.32%)
GILD   66.45 (-0.79%)
S&P 500   3,834.85 (-0.47%)
DOW   30,934.64 (-0.77%)
QQQ   325.24 (-0.34%)
AAPL   135.28 (-1.16%)
MSFT   227.32 (+1.04%)
FB   273.05 (+0.07%)
GOOGL   1,879.03 (-0.27%)
AMZN   3,285.75 (-0.64%)
TSLA   839.70 (-0.63%)
NVDA   547.12 (-1.37%)
BABA   257.09 (-1.12%)
CGC   33.32 (-0.72%)
GE   11.08 (+0.09%)
MU   84.58 (-0.51%)
AMD   95.40 (+4.23%)
NIO   58.68 (+0.58%)
T   28.65 (-0.62%)
F   11.59 (+0.52%)
ACB   10.29 (-7.88%)
BA   206.00 (-0.68%)
DIS   174.12 (+1.66%)
NFLX   581.69 (+0.32%)
GILD   66.45 (-0.79%)
S&P 500   3,834.85 (-0.47%)
DOW   30,934.64 (-0.77%)
QQQ   325.24 (-0.34%)
AAPL   135.28 (-1.16%)
MSFT   227.32 (+1.04%)
FB   273.05 (+0.07%)
GOOGL   1,879.03 (-0.27%)
AMZN   3,285.75 (-0.64%)
TSLA   839.70 (-0.63%)
NVDA   547.12 (-1.37%)
BABA   257.09 (-1.12%)
CGC   33.32 (-0.72%)
GE   11.08 (+0.09%)
MU   84.58 (-0.51%)
AMD   95.40 (+4.23%)
NIO   58.68 (+0.58%)
T   28.65 (-0.62%)
F   11.59 (+0.52%)
ACB   10.29 (-7.88%)
BA   206.00 (-0.68%)
DIS   174.12 (+1.66%)
NFLX   581.69 (+0.32%)
GILD   66.45 (-0.79%)
S&P 500   3,834.85 (-0.47%)
DOW   30,934.64 (-0.77%)
QQQ   325.24 (-0.34%)
AAPL   135.28 (-1.16%)
MSFT   227.32 (+1.04%)
FB   273.05 (+0.07%)
GOOGL   1,879.03 (-0.27%)
AMZN   3,285.75 (-0.64%)
TSLA   839.70 (-0.63%)
NVDA   547.12 (-1.37%)
BABA   257.09 (-1.12%)
CGC   33.32 (-0.72%)
GE   11.08 (+0.09%)
MU   84.58 (-0.51%)
AMD   95.40 (+4.23%)
NIO   58.68 (+0.58%)
T   28.65 (-0.62%)
F   11.59 (+0.52%)
ACB   10.29 (-7.88%)
BA   206.00 (-0.68%)
DIS   174.12 (+1.66%)
NFLX   581.69 (+0.32%)
GILD   66.45 (-0.79%)
Log in
NASDAQ:CGEN

Compugen Stock Forecast, Price & News

$12.60
-0.04 (-0.32 %)
(As of 01/22/2021 09:34 AM ET)
Add
Compare
Today's Range
$12.60
Now: $12.60▼
$12.71
50-Day Range
$12.07
MA: $12.83▼
$14.19
52-Week Range
$5.94
Now: $12.60▼
$19.90
Volume301 shs
Average Volume1.21 million shs
Market Capitalization$862.09 million
P/E RatioN/A
Dividend YieldN/A
Beta2.52
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Compugen logo

MarketRank™

Overall MarketRank™

1.39 out of 5 stars

Medical Sector

556th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

73rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGEN
Previous Symbol
CUSIPN/A
CIK1119774
Webwww.cgen.com
Phone972-3765-8585
Employees61

Debt

Debt-to-Equity RatioN/A
Current Ratio16.93
Quick Ratio16.93

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.80 million
Price / Sales48.43
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.75 per share
Price / Book16.80

Profitability

EPS (Most Recent Fiscal Year)($0.43)
Net Income$-27,340,000.00
Net MarginsN/A
Return on Equity-26.98%
Return on Assets-23.28%

Miscellaneous

Outstanding Shares68,420,000
Market Cap$862.09 million
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$12.60
-0.04 (-0.32 %)
(As of 01/22/2021 09:34 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Compugen (NASDAQ:CGEN) Frequently Asked Questions

How has Compugen's stock price been impacted by COVID-19?

Compugen's stock was trading at $11.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CGEN stock has increased by 6.8% and is now trading at $12.64.
View which stocks have been most impacted by COVID-19.

Is Compugen a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Compugen stock.
View analyst ratings for Compugen or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Compugen?

Wall Street analysts have given Compugen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Compugen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Compugen's CEO?

1,448 employees have rated Compugen CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Compugen's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Compugen's next earnings date?

Compugen is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Compugen.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) posted its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.09). The business's quarterly revenue was up .0% compared to the same quarter last year.
View Compugen's earnings history.

What price target have analysts set for CGEN?

8 brokerages have issued twelve-month price objectives for Compugen's stock. Their forecasts range from $13.00 to $28.00. On average, they anticipate Compugen's share price to reach $19.75 in the next year. This suggests a possible upside of 56.3% from the stock's current price.
View analysts' price targets for Compugen or view Wall Street analyst' top-rated stocks.

Are investors shorting Compugen?

Compugen saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 4,690,000 shares, an increase of 73.1% from the December 15th total of 2,710,000 shares. Based on an average daily volume of 1,120,000 shares, the days-to-cover ratio is presently 4.2 days.
View Compugen's Short Interest.

Who are some of Compugen's key competitors?

Some companies that are related to Compugen include Kymera Therapeutics (KYMR), NanoString Technologies (NSTG), bluebird bio (BLUE), AlloVir (ALVR), Revolution Medicines (RVMD), Sorrento Therapeutics (SRNE), Bavarian Nordic A/S (BVNRY), Sangamo Therapeutics (SGMO), Replimune Group (REPL), NantKwest (NK), Vericel (VCEL), Scholar Rock (SRRK), Translate Bio (TBIO), BioCryst Pharmaceuticals (BCRX) and REGENXBIO (RGNX).
View all of CGEN's competitors.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

Who are Compugen's key executives?

Compugen's management team includes the following people:
  • Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 54, Pay $700.9k)
  • Mr. Ari Krashin, Chief Financial & Operating Officer (Age 48, Pay $390.49k)
  • Ms. Elana Holzman, Director of Investor Relations & Corp. Communications
  • Ms. Donna Gershowitz, Gen. Counsel (Age 57)
  • Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 52)
  • Dr. Oliver Froescheis Ph.D., Sr. VP of Corp. & Bus. Devel. (Age 55)
  • Ms. Dorit Amitay, VP of HR (Age 53)
  • Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 53, Pay $257.25k)
  • Dr. Henry Adewoye M.D., Chief Medical Officer (Age 56, Pay $502.51k)
  • Dr. Yaron Turpaz M.B.A., Ph.D., MBA, Sr. VP & Sr. Advisor of Computational Discovery

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (0.83%).

Which institutional investors are buying Compugen stock?

CGEN stock was purchased by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $12.64.

How big of a company is Compugen?

Compugen has a market capitalization of $864.83 million and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 61 workers across the globe.

What is Compugen's official website?

The official website for Compugen is www.cgen.com.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.